A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|10|1717-1724

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.10, 2015-10, pp. : 1717-1724

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 751-758

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I trial of Seneca Valley Virus (NTX‐010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 743-750

John Wiley & Sons Inc

Access to resources Recommend Favorite

Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 7, 2015-07 ,pp. : 1171-1175

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1562-1566

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 4, 2015-04 ,pp. : 603-610

John Wiley & Sons Inc

Access to resources Recommend Favorite